Per recent study, patients with B-cell NHL (non-Hodgkins Lymphoma) who failed to respond to prior treatment therapies show positive results when given mosunetuzumab, a new investigational drug. This new drug targets two proteins, one on the surface of tumor cells and the other on the surface of the recipient’s T cells. The study has been...